Swecure AB Information

Swecure is a Swedish biotechnology company developing pharmaceuticals for immunoregulatory disorders such as a preventive treatments for allergies and treatments for other chronic diseases. The company is working to reduce the prevalence of allergies and to improve the quality of life for mankind. Swecure is based out of research in bacteriology and immunology from Sahlgrenska University Hospital with 15 years of experience in infant gut bacterial flora. Swecure’s technology represents the world’s first prophylactic approach to allergies. No similar product exists on the market or in the current pipeline of any big pharmaceutical company. Swecure however has identified a bacterial protein with the unique ability to activate immunological tolerance mechanisms in the first weeks of life, stopping allergies before they even develop. Swecure is a portfolio company of Serendipity Ixora, a venture capital firm specializing in research-intensive ventures.